Innovo Therapeutics is committed to discovering and developing the next generation of protein degraders in areas of high unmet medical need. Our extensive experience in drug discovery, combined with our unique expertise in targeted protein degradation, allows us to quickly develop an extensive compound library of novel and drug-like structures which generates high-quality leads. We have a powerful targeted protein degradation platform called TriNovo. Coupled with a proprietary phenotypic screening platform, our scientists build and rapidly expand a high-quality, differentiated pipeline. Our competitive advantage is a differentiated drug discovery approach, allowing us to advance our pipeline quickly. We continue to drive value through highly validated biology and our differentiated, high-throughput chemistry platform. We focus on execution, rapidly growing our pipeline through corporate and academic alliances. We have worldwide exclusive rights to Rosmantuzumab, anti-RSPO3 mAB, which is a Phase 2 clinical program. We are actively engaged in further pharma partnership discussions to advance our pipeline programs. We are maximizing Innovo’s expertise, productivity, and efficiency with the Innovo US team’s proven drug discovery experience, leveraging our expertise, and optimizing China’s rich pre-clinical resources and infrastructure to build a world-class, global biopharma company.
Company Details
- Employees
- 9
- Founded
- -
- Address
- 10355 Science Center Dr, San Diego,california 92121,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Targeted Protein Degradation Drug Discovery, Oncology Drug Development, Molecular Glues, Protac, Immunology.
- HQ
- San Diego, California
Innovo Therapeutics Questions
Innovo Therapeutics's website is https://www.innovotherapeutics.com/
Innovo Therapeutics's LinkedIn profile is https://www.linkedin.com/company/innovo-therapeutics
Innovo Therapeutics has
9 employees.
View email and phone details for 9
employees at Innovo Therapeutics.
Innovo Therapeutics's industry is
Biotechnology Research
Innovo Therapeutics's top competitors are
Equillium, Inc.,
Biotheryx, Inc.,
Kura Oncology, Inc.,
Innovo Therapeutics Inc.,
Kumquat Biosciences Inc.,
Multiverse Pharma Inc.,
Erasca, Inc.,
K36 Therapeutics, Inc.,
Boundless Bio,
Janux Therapeutics.
Innovo Therapeutics's categories are Biotechnology Research
Innovo Therapeutics's founding year is 2021
